HeartSciences Inc.
HSCS Healthcare Medical Devices
HeartSciences Inc.’s revenue for fiscal 2026 (year ended April 2026) was $4,300.00, down 2.27% from fiscal 2025. In the quarter to July 2026, revenue fell 46.2%, EPS grew 45.6% and free cash flow grew 18.2%, each against the same quarter a year earlier.
Follow HSCS
HeartSciences Inc. (HSCS) Altman Z-score
HeartSciences Inc.'s Altman Z-score for fiscal 2026 is −27.87, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −27.87 | 3.84 |
| FY2025 | −31.71 | (21.19) |
| FY2024 | −10.51 | 19.80 |
| FY2023 | −30.31 | — |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.43) | — | −0.52 | |
| Retained earnings / total assets | (16.20) | — | −22.68 | |
| EBIT / total assets | (1.60) | — | −5.28 | |
| Market value of equity / total liabilities | 1.02 | — | 0.61 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −27.87 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −66.36 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IRIX IRIDEX Corporation compare | −2.0× |
| PAVM PAVmed Inc. compare | −11.4× |
| LFWD Lifeward Ltd. compare | −18.8× |
| HSCS HeartSciences Inc. | −27.9× |
| ALUR Allurion Technologies, Inc. compare | −29.6× |
| PETV PetVivo Holdings, Inc. compare | −38.6× |
| SINT SINTX TECHNOLOGIES, INC. compare | −45.4× |
| RBOT Vicarious Surgical Inc. compare | — |
| BDMD Baird Medical Investment Holdings Limited compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets